What to Expect When Starting Apixaban
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Introduction
Apixaban (Eliquis) is a direct oral anticoagulant (DOAC) that prevents blood clots by inhibiting Factor Xa. It is used to prevent stroke in atrial fibrillation, treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevent clots after joint replacement surgery. Unlike warfarin, apixaban does not require regular INR blood test monitoring and has fewer food and drug interactions.
Week-by-week timeline
Starting Anticoagulation
Apixaban reaches peak blood levels within 3-4 hours of the first dose. For DVT/PE treatment, a higher 'loading' dose is used for the first 7 days (10 mg twice daily), then reduced to the maintenance dose (5 mg twice daily). You are protected from clotting quickly, but bleeding risk also begins immediately.
Monitoring for Bleeding
Watch for unusual bruising, prolonged bleeding from cuts, pink or dark urine, or red/black stools. These may indicate excess bleeding. For joint replacement patients, watch the surgical site. Minor bruising is common and expected.
Establishing a Routine
Take apixaban at the same times each day, approximately 12 hours apart. If you miss a dose, take it as soon as you remember the same day. Do not double up. Carry an anticoagulant ID card in case of emergency.
Provider Follow-Up
Your doctor will assess your response, review your bleeding history, and ensure no drug interactions have emerged. Kidney function and liver function may be checked, as apixaban clearance depends on these organs.
Long-Term Anticoagulation
Duration of therapy varies: 3-6 months for provoked DVT/PE, indefinitely for unprovoked clots or AFib. Discuss the plan with your provider. Never stop apixaban without talking to your doctor — abrupt discontinuation significantly raises stroke or clot risk.
When to call your doctor
Contact your healthcare provider if you experience:
- Coughing or vomiting blood
- Red, pink, or dark brown urine
- Red or black tarry stools (signs of GI bleeding)
- Severe headache, dizziness, or weakness (possible intracranial bleeding)
- Unusual bruising that is large or growing rapidly
- Prolonged bleeding from a cut that won't stop
- Joint pain or swelling (possible joint bleeding)
- Spinal or epidural hematoma symptoms: back pain, numbness/weakness in legs, loss of bladder/bowel control (if you have had a spinal procedure)
Tips for getting started
Never stop apixaban without consulting your doctor — stopping suddenly dramatically increases stroke or clot risk. Take doses 12 hours apart and set phone reminders. Always tell every healthcare provider (dentists, surgeons) that you take apixaban before any procedure. Get an anticoagulant wallet card. Avoid NSAIDs (ibuprofen, naproxen) and aspirin unless specifically directed by your doctor, as they increase bleeding risk. Andexanet alfa (Andexxa) is the reversal agent available in hospitals if serious bleeding occurs.
Frequently asked questions
More about Apixaban
References
- [Regulatory] FDA Label: Eliquis (apixaban) Tablets https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202155s030lbl.pdf Accessed 2026-03-01.
- [Regulatory] NIH MedlinePlus: Apixaban https://medlineplus.gov/druginfo/meds/a692044.html Accessed 2026-03-01.
- [Clinical] ACC/AHA AFib Guidelines: Anticoagulation https://www.jacc.org/doi/10.1016/j.jacc.2019.01.011 Accessed 2026-03-01.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: